These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Poirel HA; Bernheim A; Schneider A; Meddeb M; Choquet S; Leblond V; Charlotte F; Davi F; Canioni D; Macintyre E; Mamzer-Bruneel MF; Hirsch I; Hermine O; Martin A; Cornillet-Lefebvre P; Patey M; Toupance O; Kémény JL; Deteix P; Raphaël M Transplantation; 2005 Jul; 80(2):176-84. PubMed ID: 16041261 [TBL] [Abstract][Full Text] [Related]
6. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Végso G; Hajdu M; Sebestyén A Pathol Oncol Res; 2011 Sep; 17(3):443-54. PubMed ID: 21193979 [TBL] [Abstract][Full Text] [Related]
7. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. Krisl JC; Doan VP Am J Transplant; 2017 Aug; 17(8):1974-1991. PubMed ID: 28394486 [TBL] [Abstract][Full Text] [Related]
9. Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. Engels EA Am J Transplant; 2019 Dec; 19(12):3223-3232. PubMed ID: 31206226 [TBL] [Abstract][Full Text] [Related]
10. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Preiksaitis JK Clin Infect Dis; 2004 Oct; 39(7):1016-23. PubMed ID: 15472855 [TBL] [Abstract][Full Text] [Related]
16. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Lim WH; Russ GR; Coates PT Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577 [TBL] [Abstract][Full Text] [Related]
17. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Tsao L; Hsi ED Arch Pathol Lab Med; 2007 Aug; 131(8):1209-18. PubMed ID: 17683183 [TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Allen UD; Preiksaitis JK; Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381 [TBL] [Abstract][Full Text] [Related]
19. Post-transplant malignancy: the role of immunosuppression. Penn I Drug Saf; 2000 Aug; 23(2):101-13. PubMed ID: 10945373 [TBL] [Abstract][Full Text] [Related]
20. Solid Organ Transplantation and Survival among Individuals with a History of Cancer. Engels EA; Haber G; Hart A; Lynch CF; Li J; Pawlish KS; Qiao B; Yu KJ; Pfeiffer RM Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1312-1319. PubMed ID: 33926864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]